Professor & H.O.D at Owaisi Hospital and Research Centre
Biography
In The Lancet Rheumatology, Giulio Cavalli and colleagues 1
report potential beneficial effects of the IL-1 receptor antagonist anakinra in patients with COVID-19, acute respiratory distress syndrome (ARDS), and hyperinflammation. In the study protocol, anakinra was given in combination with a 4-aminoquinoline and, although promising, we suggest that this combination cannot be fully synergistic in the presence of cytokine release syndrome.
+44 1478 350008